U.S. markets closed

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.26-0.89 (-4.90%)
At close: 4:00PM EDT

17.26 -0.00 (-0.00%)
After hours: 4:53PM EDT

Intercept Pharmaceuticals, Inc.

10 Hudson Yards
37th floor
New York, NY 10001
United States
646 747 1000

Full Time Employees498

Key Executives

NameTitlePayExercisedYear Born
Mr. Jerome B. DursoPres & CEO853.17kN/A1968
Dr. Mark PruzanskiFounder, Advisor & Director1.3MN/A1968
Dr. Christian WeyerExec. VP of R&D679.45kN/A1970
Mr. Rocco VeneziaChief Accounting Officer, Treasurer & Acting CFON/AN/AN/A
Ms. Lisa M. DeFrancescoSr. VP of Corp. Affairs & Investor RelationsN/AN/A1979
Mr. Jared M. FreedbergGen. Counsel & Sec.N/AN/A1969
Mr. David FordChief HR OfficerN/AN/A1970
Dr. Gail CawkwellSr. VP of Medical Affairs, Safety & Pharmacovigilance and Acting Chief Medical OfficerN/AN/A1963
Ms. Linda M. RichardsonExec. VP & Chief Commercial OfficerN/AN/A1964
Mr. Bryan BallChief Quality OfficerN/AN/A1970
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.

Corporate Governance

Intercept Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 5. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 6; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.